Filing Flows › Volitionrx (VNRX) › Q2 2025
Volitionrx (VNRX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Volitionrx (VNRX) reported revenue of $407K for the second quarter 2025 (Q2 2025), +3% from a year earlier and +65% from the quarter before.
Volitionrx, Q2 2025: revenue $407K (+3% year over year), net loss $6.3M, operating cash flow −$6.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $407K | +65% | +3% |
| Operating profit | −$6.3M | — | — |
| Net earnings | −$6.3M | — | — |
| Operating cash flow | −$6.3M | — | — |
What changed
Revenue was $407K in Q2 2025, up 3% year over year and up 65% from the previous quarter.
Operating costs exceeded revenue by $6.3M, an operating margin of -1548.6%. Total costs fell 9% while revenue rose 3%. The fastest-growing cost line was General & admin (+29%). The quarter ended with a net loss of $6.3M, wider than the previous quarter's $5.5M loss. Minority interests bore $30K of it: to shareholders the quarter was a loss of $6.3M.
Operating cash flow was −$6.3M. Non-cash charges added back $253K of depreciation and amortization and $812K of share-based compensation. Working capital and other items used $1.0M. Capital expenditures of $77K exceeded it, leaving free cash flow of −$6.3M.
Questions
What was Volitionrx's revenue in the second quarter 2025?
Volitionrx (VNRX) reported revenue of $407K for the second quarter 2025 (Q2 2025), +3% from a year earlier and +65% from the quarter before.
Source: Volitionrx 10-Q on SEC EDGAR.